logo

Clearside Biomedical, Inc. (CLSD)



Trade CLSD now with
  Date
  Headline
10/25/2021 6:47:09 AM Bausch + Lomb,Clearside Biomedical: FDA Approves XIPERE For Suprachoroidal Use For Macular Edema Associated With Uveitis
9/21/2021 7:13:05 AM Clearside Biomedical Announces Completion Of Dosing In Cohort 2 Of Phase 1/2a Trial Of CLS-AX In Wet AMD Patients
8/15/2021 9:48:40 PM Arctic Vision Expands License Territory For Suprachoroidal Space Injection Therapy ARVN001 To Include ASEAN Countries
6/15/2021 7:09:27 AM Clearside Biomedical Announces Positive Results From Cohort 1 Of OASIS Phase 1/2a Clinical Trial Of CLS-AX In Wet AMD
6/2/2021 7:25:15 AM Bausch Health And Clearside Biomedical Announce FDA Filing Acceptance For XIPERE; Assigns PDUFA Action Date Of Oct 30
5/3/2021 7:11:52 AM Clearside Biomedical Announces Resubmission Of NDA For XIPERE For Treatment Of Macular Edema Associated With Uveitis
3/2/2021 7:13:47 AM Clearside Biomedical Complets Patient Dosing In First Cohort Of Phase 1/2a Clinical Trial Of CLS-AX For Wet AMD
1/12/2021 7:28:03 AM Clearside Biomedical Says First Patients Enrolled In Phase 1/2a Clinical Trial Of CLS-AX
1/6/2021 7:11:02 AM Clearside Biomedical Enters Deal For Purchase And Sale Of 4.21 Mln Shares At $2.851/Shr Priced At-the-market
1/28/2020 7:20:14 AM Bausch Health And Clearside Biomedical Announce Publication Of PIVOTAL Phase 3 Data ON XIPERETM In Ophthalmology
7/29/2019 7:18:50 AM Wedbush Reiterates Clearside Biomedical, Inc. (CLSD) At Outperform With $4 Price Target
7/10/2019 6:49:54 AM Wedbush Reiterates Clearside Biomedical, Inc. (CLSD) At Outperform With $4 Price Target
5/9/2019 7:50:06 AM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) FY20 Rev. Estimate To 7.6 M From 7.4 M